TGTX Net Income Applicable To Common Shares from 2010 to 2024

TGTX Stock  USD 31.67  1.17  3.56%   
TG Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -172.6 M in 2024. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2000-03-31
Previous Quarter
-34.1 M
Current Value
-41 M
Quarterly Volatility
27.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 444.1 K, Interest Expense of 13.2 M or Total Revenue of 245.3 M, as well as many indicators such as Price To Sales Ratio of 9.86, Dividend Yield of 4.0E-4 or PTB Ratio of 15.86. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
  
Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Latest TG Therapeutics' Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of TG Therapeutics over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. TG Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

TGTX Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(123,180,493)
Geometric Mean54,004,840
Coefficient Of Variation(83.96)
Mean Deviation84,160,681
Median(118,476,012)
Standard Deviation103,427,647
Sample Variance10697.3T
Range348.7M
R-Value(0.82)
Mean Square Error3765.2T
R-Squared0.67
Significance0.0002
Slope(18,975,021)
Total Sum of Squares149761.9T

TGTX Net Income Applicable To Common Shares History

2024-172.6 M
2023-164.4 M
2022-182.6 M
2021-348.1 M
2020-279.4 M
2019-172.9 M
2018-173.5 M

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-164.4 M-172.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.